The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial

Objective Evidence linking non-obese non-alcoholic fatty liver disease (NAFLD) with residual cholesterol (RC) is weak. In this study, Chinese adults who were not obese were examined for a relationship between NAFLD and RC levels. Methods 16,004 non-obese volunteers were included in a retrospective cohort study at a Chinese clinic between the start of 2010 and the end of 2014. The correlation between initial RC levels and the likelihood of developing NAFLD was investigated using the proportional hazards regression (Cox) model. Using cubic spline functions and smooth curve fitting technique, a two-piecewise proportional hazards regression (Cox) method was used to investigate nonlinear associations between RC and NAFLD. There were numerous sensitivity assessments carried out. The information was posted on the DATADRYAD website. Results The results showed a positive correlation between RC and incidence of NAFLD after controlling for variables (HR = 1.061, 95% CI 1.045–1.078). Between RC and NAFLD, a nonlinear connection was found, with a turning point at 98.29 mg/dL. The effect sizes (HR) were 1.150 (95% CI 1.106, 1.194) and 1.009 (95% CI 0.982, 1.037) on either side of the turning point, respectively. A sensitivity examination further supported the stability of the findings. Conclusion In a Chinese sample that is not obese, this research emphasizes a potentially favorable nonlinear connection between RC and NAFLD risk. When RC was below 98.29 mg/dL, RC was substantially associated with the risk of NAFLD. Thus, from a therapeutic standpoint, keeping RC levels below this cutoff would be advantageous.

show abstract

Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota

Sokal-Dembowska,

Jarmakiewicz-Czaja,

Filip

2024

IJMS

View full text Add to dashboard Cite

With the increasing prevalence and serious health consequences of metabolic-associated fatty liver disease (MAFLD), early diagnosis and intervention are key to effective treatment. Recent studies highlight the important role of dietary factors, including the use of flavonoids, in improving liver health. These compounds possess anti-inflammatory, antioxidant, and liver-protective properties. Flavonoids have been shown to affect the gut microbiota, which plays a key role in liver function and disease progression. Therefore, their role in preventing the development and progression of MAFLD through modulation of the microbiome seems to be of interest. This narrative review aims to consolidate the current evidence on the effects of selected flavonoids on MAFLD progression, their potential mechanisms of action, and the implications for the development of personalized dietary interventions for the management of liver disease.

show abstract

The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial

Cited by 3 publications

References 71 publications

Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021

Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021

Remnant cholesterol has a nonlinear association with non-alcoholic fatty liver disease: A secondary retrospective cohort study in non-obese Chinese adults

Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota

Contact Info

Product

Resources

About